

**Ref: 11/SE/LC/2024-25**

**Date: 15/05/2024**

To,

**Head, Listing Compliance Department  
BSE Limited**

Phiroze Jeejeebhoy Towers Dalal Street,  
Mumbai - 400 001.

**Scrip Code: 544122**

**Head, Listing Compliance Department  
National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051

**Scrip Symbol: ENTERO**

Dear Sir/Madam,

**Subject: Report of Monitoring Agency for the quarter ended March 31, 2024**

**Reference: Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ('LODR')**

Pursuant to Regulation 32(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed herewith Monitoring Agency Report issued by ICRA Limited, the Monitoring Agency, for the quarter ended March 31, 2024, in respect of the utilization of the proceeds of the Initial Public Offer ("IPO") of the Company.

The Monitoring Agency Report is also available on website of the Company [www.enterohealthcare.com](http://www.enterohealthcare.com)

This is for your information and records.

Yours Faithfully

**For Entero Healthcare Solutions Limited**

Jayant Prakash

**General Counsel, Company Secretary & Compliance Officer**

(Mem: F6742)

Encl: Monitoring Agency Report issued by ICRA Limited



ICRA Limited

**Date: May 14, 2024**

Mr. C. V. Ram  
CFO

**Entero Healthcare Solutions Limited**

Unit No. 605-606, Trade Centre  
Bandra Kurla Complex,  
Bandra East, Mumbai - 400051

Dear Madam,

**Re: Final Monitoring Agency report of Entero Healthcare Solutions Limited for Q4 FY2024**

Please refer to agreement dated February 01, 2024, appointing ICRA Limited as the Monitoring Agency (MA) for Entero Healthcare Solutions Limited's IPO Issue.

After due consideration, ICRA has prepared the attached final Monitoring Agency report as per SEBI (Issue of Capital and Disclosure Requirements) Regulations for Q4 FY2024.

Please note that the Monitoring Agency report does not constitute a commentary on the quality of the objects of the issue, appropriateness or reasonableness of costs or spending by Entero Healthcare Solutions Limited against any objects / heads or assurance on outcome of such spending.

We thank you for your kind cooperation extended during the course of Q4 FY2024. Should you require any clarification, please do not hesitate to get in touch with us.

We look forward to your communication and assure you of our best services.

With kind regards

For ICRA Limited

**PARUL**  
**GOYAL**  
**NARANG**

Digitally signed  
by PARUL  
GOYAL NARANG  
Date: 2024.05.14  
19:57:54 +05'30'

Parul Goyal Narang  
Vice President & Head- Process Excellence  
Parul.goyal@icraindia.com

Building No. 8, 2<sup>nd</sup> Floor, Tower A  
DLF Cyber City, Phase II  
Gurugram – 122002, Haryana

Tel.: +91.124 .4545300  
CIN : L749999DL1991PLC042749

Website: www.icra.in  
Email: info@icraindia.com  
Helpdesk: +91 9354738909

Registered Office: B-710, Statesman House, 148, Barakhamba Road, New Delhi 110001. Tel. :+91.11.23357940-41

**RATING • RESEARCH • INFORMATION**



MONITORING AGENCY REPORT

**Name of the Issuer:** Entero Healthcare Solutions Limited

**For quarter ended:** March 31, 2024

**Name of the Monitoring Agency (MA):** ICRA Limited

**(a) Deviation from the objects of the issue:**

No material deviation - the utilization of the issuance proceeds is in line with the objects of the issue.

**(b) Range of deviation:**

*Not Applicable*

**Declaration:**

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that we do not perceive any conflict of interest in such relationship/ interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

**Signature:**

PARUL  
GOYAL  
NARANG  
G

Digitally signed  
by PARUL  
GOYAL NARANG  
Date:  
2024.05.14  
19:55:45 +05'30'

Parul Goyal Narang  
Vice President & Head- Process Excellence

Analyst: Subhechha Banerjee  
Quality Analyst: Dhvani Vinchhi

**1. Issuer Details****Name of the Issuer:** Entero Healthcare Solutions Limited**Name(s) of the promoters:**

Promoters
<i>Prabhat Agrawal</i>
<i>Prem Sethi</i>
<i>Orbimed Asia III Mauritius Limited</i>

Source: BSE

**Industry/ sector to which it belongs:** Healthcare Product Distributor.**2. Issue Details****Issue Period:** Opening date- February 09, 2024

Closing date- February 13, 2024

**Type of Issue:** Initial Public Offer**Type of specified securities:** Equity shares**IPO Grading, if any:** No credit rating agency registered with SEBI has been appointed in respect of obtaining grading for the offer.**Issue Size (Rs. Crore):** INR 1600.000 crores

With OFS portion: INR 1600.000 Crore; Excluding OFS portion: INR 1000.000 Crore.

Net proceeds as per Prospectus: INR 951.200 Crore (Excluding Issue Related Expenses)

The proceeds credited to the Net Proceeds account stood at INR 951.330 Crore as issue related expenses (IRE) incurred were lower than the estimated by INR 0.130 Crore. Hence ICRA will be monitoring the revised Net Proceeds amount of INR 951.330 Crore

**3. Details of the arrangement made to ensure the monitoring of issue proceeds.**

Particulars	Reply	Source of information, certifications considered by the Monitoring Agency for the preparation of report	Comments of the Monitoring Agency	Comments of the Issuer's Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	<b>Yes</b>	-Peer Review CA Certificate -Confirmation from management -Bank statement of the proceeds account	<i>No deviation observed.</i>	
Whether shareholder approval has been obtained in case of material deviations <sup>#</sup> from expenditures disclosed in the Offer Document?	<b>Not Applicable</b>	<i>As confirmed by the Issuer's management</i>	<i>No comments</i>	
Whether the means of finance for the disclosed objects of the issue has changed?	<b>No</b>	<i>As confirmed by the Issuer's management</i>	<i>No comments</i>	
Is there any major deviation observed over the earlier monitoring agency reports?	<b>Not Applicable</b>	<i>No deviation observed.</i>	<i>No comments</i>	
Whether all Government/ statutory approvals related to the object(s) have been obtained?	<b>Not Applicable</b>	<i>As confirmed by the Issuer's management</i>	<i>No comments</i>	
Whether all arrangements pertaining to technical assistance/ collaboration are in operation?	<b>Not Applicable</b>	<i>As confirmed by the Issuer's management</i>	<i>No comments</i>	
Are there any favorable events improving the viability of these object(s)?	<b>No</b>	<i>As confirmed by the Issuer's management</i>	<i>As understood from the Issuer's management</i>	
Are there any unfavorable events affecting the viability of the object(s)?	<b>No</b>	<i>As confirmed by the Issuer's management</i>	<i>As understood from the Issuer's management</i>	
Is there any other relevant information that may materially affect the decision making of the investors?	<b>No</b>	<i>As confirmed by the Issuer's management</i>	<i>As understood from the Issuer's management</i>	

<sup>#</sup> Where material deviation is defined to mean:

- (a) Deviation in the objects or purposes for which the funds had been raised.
- (b) Deviation in the amount of funds utilized by more than 10% of the amount specified in the offer document.

**4. Details of the object(s) to be monitored.**
**(i) Cost of object(s)**

S.N.	Item Head	Source of information, certifications considered by the Monitoring Agency for the preparation of report	Original cost (as per the offer document) [Rs. Crore]	Revised cost [Rs. Crore]	Comments of the Monitoring Agency	Comments of the Issuer's Board of Directors		
						Reason for cost revision	Proposed financing option	Particulars of firm arrangements made
1	Repayment/prepayment, in full or part, of certain borrowings availed of by our Company	Prospectus	142.500	-	No Comments			
2	Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026	Prospectus	480.000	-	No Comments			
3	Pursuing inorganic growth initiatives through acquisitions	Prospectus	237.000	-	No Comments			
4	General corporate purposes	Prospectus	91.700	91.830	Revision in General Corporate Purpose is on account of actual offer related expenditure being lower than estimated by INR 0.13 Crore			
	<b>Total</b>		<b>951.200</b>	<b>951.330</b>				

## (ii) Progress in the object(s)

S.N.	Item Head*	Source of information, certifications considered by the Monitoring Agency for the preparation of report	Amount as proposed in the offer document [Rs. Crore]	Amount utilized [Rs. Crore]			Total unutilized amount [Rs. Crore]	Comments of the Monitoring Agency	Comments of the Issuer's Board of Directors	
				As at the beginning of the quarter	During the quarter	At the end of the quarter			Reasons for idle funds	Proposed course of action
1	Repayment/prepayment, in full or part, of certain borrowings availed of by our Company	-Peer Reviewed CA Certificate -Bank statement of the proceeds account -Prospectus	142.500	-	142.500	142.500	Nil	No comments		
2	Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026	Same as above	480.000	-	157.950	157.950	322.050	No comments		
3	Pursuing inorganic growth initiatives through acquisitions	Same as above	237.000	-	-	-	237.000	No comments		
4	General corporate purposes	Same as above	91.700 (91.830)*	-	10.270	10.270	81.560	Revision in General Corporate Purpose is on account of actual offer related expenditure being lower than estimated by INR 0.13 Crore		
	<b>Total</b>		<b>951.330</b>	<b>-</b>	<b>310.720</b>	<b>310.720</b>	<b>640.610</b>			

\*Revised cost as per point no 4(i) above

## (iii) Deployment of unutilized proceeds

S.N.	Type of instrument and name of the entity invested in	Amount invested [Rs. Crore]	Maturity date	Earning [Rs. Crore]	Return on Investment [%]	Market Value as at the end of quarter* [Rs. Crore]
1	Fixed Deposit with HDFC	237.000	February 17, 2025	2.16	0.9%	238.94
2	Fixed Deposit with Axis Bank	322.000	February 20, 2025	3.00	0.9%	322.00
3	Fixed Deposit with ICICI	31.560	February 21, 2025	0.29	0.9%	31.82
4	Fixed Deposit with ICICI	50.000	February 28, 2025	0.38	0.8%	50.34
5	Current Account with Axis bank	0.050	NA	NA	NA	0.05
<b>Total</b>		<b>640.610</b>	<b>-</b>	<b>5.830</b>	<b>-</b>	<b>643.150</b>

Source: As certified by A R C K &amp; Co.

## (iv) Delay in the implementation of the object(s)

Object(s)	Completion date			Comments of the Issuer's Board of Directors	
	As per the offer document	Actual <sup>^</sup>	Delay [Number of days or months]	Reason for delay	Proposed course of action
<i>Repayment/prepayment, in full or part, of certain borrowings availed of by our Company</i>	<i>FY 2024</i>	<i>On Schedule</i>	<i>NA</i>		
<i>Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026</i>	<i>FY 2026</i>	<i>On Schedule</i>	<i>NA</i>		
<i>Pursuing inorganic growth initiatives through acquisitions</i>	<i>FY 2025</i>	<i>On Schedule</i>	<i>NA</i>		
<i>General corporate purposes</i>	<i>FY 2026</i>	<i>On Schedule</i>	<i>NA</i>		

Source: Prospectus

## 5. Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document

S.N.	Item Head	Amount [Rs. Crore]	Source of information, certifications considered by the Monitoring Agency for the preparation of report	Comments of the Monitoring Agency	Comments of the Issuer's Board of Directors
<b>1</b>	<i>Redemption Premium of NCD including Interest</i>	<i>3.230</i>	<i>-Peer Reviewed CA Certificate -Bank statement of the proceeds account</i>	<i>No comments</i>	
<b>2</b>	<i>Salary Payment</i>	<i>7.040</i>	<i>-Peer Reviewed CA Certificate -Bank statement of the proceeds account</i>	<i>No comments</i>	
	<b>Total</b>	<b>10.270</b>			